US6218410B1
(en)
|
1996-08-12 |
2001-04-17 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Medicines comprising Rho kinase inhibitor
|
US20080233098A1
(en)
*
|
1997-10-31 |
2008-09-25 |
Mckerracher Lisa |
RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
|
EP1074545A4
(de)
*
|
1998-04-23 |
2001-08-22 |
Hiroyoshi Hidaka |
Isochinolinsulfonamid-derivate und sie als aktiven bestandteil enthaltende medikamente
|
WO2000009162A1
(fr)
*
|
1998-08-17 |
2000-02-24 |
Senju Pharmaceutical Co., Ltd. |
Medicaments preventifs/curatifs pour le glaucome
|
US7169783B2
(en)
|
1998-11-02 |
2007-01-30 |
Universite De Montreal |
(+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
|
AU3328600A
(en)
*
|
1999-03-25 |
2000-10-16 |
Santen Pharmaceutical Co. Ltd. |
Ocular tension-lowering agents
|
EP1163910B1
(de)
*
|
1999-03-25 |
2007-09-26 |
Mitsubishi Pharma Corporation |
Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
|
CA2369552A1
(en)
*
|
1999-04-22 |
2000-11-02 |
Hisashi Kai |
Agent for prophylaxis and treatment of angiostenosis
|
AU4144400A
(en)
*
|
1999-04-27 |
2000-11-10 |
Mitsubishi Pharma Corporation |
Preventives/remedies for liver diseases
|
AU5250400A
(en)
*
|
1999-06-18 |
2001-01-09 |
Mitsubishi Pharma Corporation |
Osteogenesis promoters
|
JP2001081031A
(ja)
*
|
1999-08-30 |
2001-03-27 |
Schering Ag |
溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
|
WO2001017562A1
(en)
*
|
1999-09-02 |
2001-03-15 |
Yamanouchi Pharmaceutical Co., Ltd. |
Osteogenesis promoting agents
|
WO2001022997A1
(fr)
*
|
1999-09-29 |
2001-04-05 |
Mitsubishi Pharma Corporation |
Analgesiques
|
US7217722B2
(en)
|
2000-02-01 |
2007-05-15 |
Kirin Beer Kabushiki Kaisha |
Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
|
CA2403321C
(en)
*
|
2000-03-16 |
2009-07-14 |
Mitsubishi Pharma Corporation |
Amide compounds and use thereof
|
WO2001074391A1
(fr)
*
|
2000-03-31 |
2001-10-11 |
Mitsubishi Pharma Corporation |
Agent de prevention / remedes contre les maladies renales
|
CN100548375C
(zh)
|
2000-06-23 |
2009-10-14 |
田边三菱制药株式会社 |
抗肿瘤作用增效剂
|
MXPA03002411A
(es)
*
|
2000-09-20 |
2003-06-19 |
Merck Patent Gmbh |
4-amino-quinazolinas.
|
AU2001293817A1
(en)
*
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
JP4582561B2
(ja)
*
|
2000-10-23 |
2010-11-17 |
旭化成ファーマ株式会社 |
移植による血管病変の発生抑制剤
|
JP2002139493A
(ja)
*
|
2000-11-01 |
2002-05-17 |
Sumitomo Pharmaceut Co Ltd |
新規なハイスループット・スクリーニング方法
|
CA2325842C
(en)
|
2000-11-02 |
2007-08-07 |
Lisa Mckerracher |
Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
|
US20020177207A1
(en)
*
|
2001-03-14 |
2002-11-28 |
Myriad Genetics, Incorporated |
Tsg101-interacting proteins and use thereof
|
WO2002053143A2
(en)
*
|
2001-01-05 |
2002-07-11 |
The Medical College Of Georgia Research Institute, Inc. |
Treatment of erectile dysfunction with rho-kinase inhibitors
|
JP2002226375A
(ja)
*
|
2001-01-31 |
2002-08-14 |
Asahi Kasei Corp |
線維化予防、治療剤
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
AU2002245709A1
(en)
*
|
2001-03-23 |
2002-10-08 |
Bayer Corporation |
Rho-kinase inhibitors
|
PT1370553E
(pt)
*
|
2001-03-23 |
2006-09-29 |
Bayer Corp |
Inibidores de rhoquinase
|
EP1378247B1
(de)
*
|
2001-04-11 |
2016-08-24 |
Senju Pharmaceutical Co., Ltd. |
Wirkstoffe zur behandlung von sehfunktionsstörungen
|
US7442686B2
(en)
|
2001-04-12 |
2008-10-28 |
Bioaxone Therapeutique Inc. |
Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
|
US7199147B2
(en)
*
|
2001-06-12 |
2007-04-03 |
Dainippon Sumitomo Pharma Co., Ltd. |
Rho kinase inhibitors
|
JP5042419B2
(ja)
*
|
2001-08-15 |
2012-10-03 |
旭化成ファーマ株式会社 |
骨形成促進剤および骨形成促進組成物
|
US7829566B2
(en)
*
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
DE10153605A1
(de)
*
|
2001-11-02 |
2003-05-28 |
Morphochem Ag Komb Chemie |
Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
|
AU2002349411A1
(en)
*
|
2001-11-30 |
2003-06-17 |
Asahi Kasei Pharma Corporation |
Remedies for primary pulmonary hypertension
|
FR2833840B1
(fr)
*
|
2001-12-21 |
2010-06-18 |
Rytek |
Methodes et compositions pour le traitement de pathologies respiratoires
|
DE60320933D1
(de)
*
|
2002-01-10 |
2008-06-26 |
Bayer Healthcare Ag |
Rho-kinase inhibitoren
|
MXPA04007191A
(es)
*
|
2002-01-23 |
2005-03-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirimidina como inhibidores de rho-quinasa.
|
MXPA04007196A
(es)
*
|
2002-01-23 |
2005-06-08 |
Bayer Pharmaceuticals Corp |
Inhibidores de rho-quinasa.
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
GB0206860D0
(en)
*
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Compounds
|
US20050182040A1
(en)
*
|
2002-04-03 |
2005-08-18 |
Naonori Imazaki |
Benzamide derivatives
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040028716A1
(en)
*
|
2002-06-14 |
2004-02-12 |
Marks Andrew R. |
Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
AU2003281152A1
(en)
*
|
2002-07-12 |
2004-02-02 |
Yihai Cao |
A method for inhibiting vascular permeability and tissue edema
|
WO2004009555A1
(ja)
*
|
2002-07-22 |
2004-01-29 |
Asahi Kasei Pharma Corporation |
5−置換イソキノリン誘導体
|
US7094789B2
(en)
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
DE10233737A1
(de)
*
|
2002-07-24 |
2004-02-05 |
Morphochem Aktiengesellschaft für kombinatorische Chemie |
Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
|
US20040105860A1
(en)
*
|
2002-08-01 |
2004-06-03 |
Losordo Douglas W. |
Cell modulation using a cytoskeletal protein
|
ATE546143T1
(de)
*
|
2002-08-29 |
2012-03-15 |
Santen Pharmaceutical Co Ltd |
Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
|
CA2400996A1
(en)
*
|
2002-09-03 |
2004-03-03 |
Lisa Mckerracher |
1,4-substituted cyclohexane derivatives
|
CA2502583A1
(en)
*
|
2002-09-12 |
2004-03-25 |
Kirin Beer Kabushiki Kaisha |
Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same
|
US20050215601A1
(en)
*
|
2002-09-25 |
2005-09-29 |
Santen Pharmaceutical Co., Ltd. |
Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
ES2444841T3
(es)
*
|
2002-11-18 |
2014-02-27 |
Santen Pharmaceutical Co., Ltd. |
Remedio para el glaucoma que comprende inhibidor de Rho cinasa y beta-bloqueante
|
AU2004221792C1
(en)
*
|
2003-03-18 |
2009-09-24 |
Medvet Science Pty. Ltd. |
A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
|
AU2003901270A0
(en)
*
|
2003-03-18 |
2003-04-03 |
Medvet Science Pty. Ltd. |
A method of modulating muscle cell functioning
|
GB2400316A
(en)
*
|
2003-04-10 |
2004-10-13 |
Richard Markoll |
Electromagnetic stimulation in patients with osteoporosis
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
ES2370245T3
(es)
|
2003-04-18 |
2011-12-13 |
Senju Pharmaceutical Co., Ltd. |
2-cloro-6,7-dimetoxi-n-[5-(1)h-indazolil]quinazolina-4-amina, dihidrocloruro de n-(1-bencil-4-piperidinil)-1h-indazol-5-amina, ácido
4-[2-(2,3,4,5,6-pentafluorofenil)acriloil]cinámico e hidrocloruro de fasudilo para uso en la recuperación de la percepción corneal.
|
WO2004106325A1
(en)
*
|
2003-05-29 |
2004-12-09 |
Schering Aktiengesellschaft |
Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
|
US20110098232A1
(en)
*
|
2003-05-30 |
2011-04-28 |
Zeilig Charles E |
Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
|
WO2004108142A2
(en)
*
|
2003-06-06 |
2004-12-16 |
The University Of Manchester |
Inhibitors of tip-1 for treatment tissue damage
|
US7160894B2
(en)
|
2003-06-06 |
2007-01-09 |
Asahi Kasei Pharma Corporation |
Tricyclic compound
|
WO2005017160A2
(en)
*
|
2003-08-13 |
2005-02-24 |
Children's Hospital Medical Center |
Mobilization of hematopoietic cells
|
JP2007535479A
(ja)
*
|
2003-08-13 |
2007-12-06 |
チルドレンズ ホスピタル メディカル センター |
GTPaseを調節するためのキメラペプチド
|
EP2272566A3
(de)
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisierung von antikörpern
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
US7371850B1
(en)
|
2003-08-20 |
2008-05-13 |
Myriad Genetics, Inc. |
Method and composition for reducing expression of ROCK-II
|
TWI344961B
(en)
|
2003-10-15 |
2011-07-11 |
Ube Industries |
Novel indazole derivative
|
WO2005056024A1
(en)
*
|
2003-12-05 |
2005-06-23 |
Children's Hospital Medical Center |
Methods of enhancing stem cell engraftment
|
JP5138938B2
(ja)
|
2003-12-19 |
2013-02-06 |
プレキシコン インコーポレーテッド |
Ret調節剤の開発のための化合物および方法
|
TW200526224A
(en)
*
|
2003-12-22 |
2005-08-16 |
Alcon Inc |
Short form c-Maf transcription factor antagonists for treatment of glaucoma
|
AU2004308911B2
(en)
*
|
2003-12-22 |
2010-08-26 |
Alcon, Inc. |
Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
|
US20050137146A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Alcon, Inc. |
Agents for treatment of glaucomatous retinopathy and optic neuropathy
|
CN1980929A
(zh)
*
|
2004-02-24 |
2007-06-13 |
比奥阿克松医疗技术股份有限公司 |
4-取代哌啶衍生物
|
WO2005094824A1
(en)
*
|
2004-03-25 |
2005-10-13 |
East Carolina University |
Methods of enhancing cancer therapy by protecting nerve cells
|
US20060115870A1
(en)
*
|
2004-03-30 |
2006-06-01 |
Alcon, Inc. |
High throughput assay for human Rho kinase activity
|
WO2005102345A1
(en)
*
|
2004-03-30 |
2005-11-03 |
Alcon, Inc. |
Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
|
US20080096238A1
(en)
*
|
2004-03-30 |
2008-04-24 |
Alcon, Inc. |
High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
|
PL1734996T3
(pl)
|
2004-04-02 |
2013-09-30 |
Univ California |
Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5
|
ES2553953T3
(es)
*
|
2004-06-03 |
2015-12-15 |
Senju Pharmaceutical Co., Ltd. |
Fármaco para la recuperación de la percepción corneal que contiene un compuesto amida
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
FR2879100B1
(fr)
|
2004-12-09 |
2007-07-06 |
Lionel Bueno |
Compositions pour le traitement des pathologies oculaires de surface et de la retine
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
ZA200704959B
(en)
*
|
2004-12-27 |
2009-04-29 |
Alcon Inc |
Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
|
US20090029970A1
(en)
*
|
2005-02-16 |
2009-01-29 |
Astellas Pharma Inc. |
Pain remedy containing rock inhibitor
|
CA2602035C
(en)
|
2005-03-18 |
2015-06-16 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
CR9465A
(es)
|
2005-03-25 |
2008-06-19 |
Surface Logix Inc |
Compuestos mejorados farmacocineticamente
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
DE602006008945D1
(de)
*
|
2005-06-28 |
2009-10-15 |
Sanofi Aventis |
Isochinolinderivate als inhibitoren von rho-kinase
|
ES2423006T3
(es)
|
2005-07-26 |
2013-09-17 |
Sanofi |
Derivados de isoquinolona sustituidos con piperidinilo como inhibidores de la cinasa Rho
|
SI1912949T1
(sl)
|
2005-07-26 |
2011-12-30 |
Sanofi Sa |
Cikloheksilamin izokinolonski derivati kot inhibitorji Rho-kinaze
|
WO2007025177A2
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
EP2258357A3
(de)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenese mit Acetylcholinesterasehemmer
|
EP1932841B1
(de)
|
2005-08-30 |
2014-01-01 |
Asahi Kasei Pharma Corporation |
Sulfonamidverbindung
|
KR20080040027A
(ko)
|
2005-09-02 |
2008-05-07 |
아스테라스 세이야쿠 가부시키가이샤 |
Rock 억제제로서 아미드 유도체
|
JP4832051B2
(ja)
*
|
2005-10-21 |
2011-12-07 |
学校法人順天堂 |
半月体形成性腎病変治療剤
|
US7985756B2
(en)
|
2005-10-21 |
2011-07-26 |
Braincells Inc. |
Modulation of neurogenesis by PDE inhibition
|
EP2111863B1
(de)
|
2005-10-26 |
2012-03-28 |
Asahi Kasei Pharma Corporation |
Fasudil in Kombination mit Bosentan zur Behandlung von pulmonaler arterieller Hypertonie
|
WO2007053596A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
EP1962853A1
(de)
*
|
2005-12-22 |
2008-09-03 |
Alcon Research, Ltd. |
(indazol-5-yl)-pyrazine und (1,3-dihydro-indol-2-on)-pyrazine zur behandlung rho-kinase-vermittelter erkrankungen und leiden
|
US7867999B1
(en)
|
2005-12-22 |
2011-01-11 |
Alcon Research, Ltd. |
Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
JP2009536667A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
5ht受容体介在性の神経新生
|
EP2025676A4
(de)
|
2006-06-08 |
2011-06-15 |
Ube Industries |
Neues indazolderivat mit spiroringstruktur in der seitenkette
|
US20090247552A1
(en)
*
|
2006-07-31 |
2009-10-01 |
Shirou Sawa |
Aqueous liquid preparation containing amide compound
|
WO2008022182A1
(en)
*
|
2006-08-16 |
2008-02-21 |
The Uab Research Foundation |
Methods for promoting coupling between bone formation and resorption
|
BRPI0716088B8
(pt)
|
2006-08-28 |
2021-05-25 |
Kyowa Hakko Kirin Co Ltd |
anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, método para produzir um anticorpo, hibridoma, e, kit
|
GB0617222D0
(en)
*
|
2006-08-31 |
2006-10-11 |
Vereniging Het Nl Kanker I |
Antibiotics
|
BRPI0716604A2
(pt)
|
2006-09-08 |
2013-04-09 |
Braincells Inc |
combinaÇÕes contendo um derivado de 4-acilaminopiridina
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
US20090036465A1
(en)
*
|
2006-10-18 |
2009-02-05 |
United Therapeutics Corporation |
Combination therapy for pulmonary arterial hypertension
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
WO2008079945A2
(en)
*
|
2006-12-20 |
2008-07-03 |
University Of South Florida |
Rock inhibitors and uses thereof
|
AR064420A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Alcon Mfg Ltd |
Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
|
KR20090094338A
(ko)
|
2006-12-27 |
2009-09-04 |
사노피-아벤티스 |
치환된 이소퀴놀린 및 이소퀴놀리논 유도체
|
JP5421783B2
(ja)
|
2006-12-27 |
2014-02-19 |
サノフイ |
Rhoキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
|
AU2007338411B2
(en)
|
2006-12-27 |
2012-08-23 |
Sanofi-Aventis |
Substituted isoquinolines and their use as Rho-kinase inhibitors
|
NZ577980A
(en)
|
2006-12-27 |
2012-01-12 |
Sanofi Aventis |
Cycloalkylamine substituted isoquinolone derivatives
|
WO2008077556A1
(en)
|
2006-12-27 |
2008-07-03 |
Sanofi-Aventis |
Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
|
BRPI0721180A2
(pt)
|
2006-12-27 |
2014-03-18 |
Sanofi Aventis |
Derivados de isoquinolina substituídos com cicloalquilamina
|
GB2458863B
(en)
*
|
2007-01-17 |
2011-10-12 |
Wisconsin Alumni Res Found |
Improved culture of stem cells
|
US8415372B2
(en)
|
2007-02-27 |
2013-04-09 |
Asahi Kasei Pharma Corporation |
Sulfonamide compound
|
EP2130828A4
(de)
|
2007-02-28 |
2010-12-29 |
Asahi Kasei Pharma Corp |
Sulfonamidderivat
|
KR101566171B1
(ko)
|
2007-03-09 |
2015-11-06 |
삼성전자 주식회사 |
디지털 저작권 관리 방법 및 장치
|
CA2682170A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Antibodies with decreased deamidation profiles
|
WO2008134828A2
(en)
|
2007-05-04 |
2008-11-13 |
Katholieke Universiteit Leuven |
Tissue degeneration protection
|
JP5234825B2
(ja)
|
2007-07-02 |
2013-07-10 |
旭化成ファーマ株式会社 |
スルホンアミド化合物及びその結晶
|
AU2008276063B2
(en)
|
2007-07-17 |
2013-11-28 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
KR20100080514A
(ko)
|
2007-08-29 |
2010-07-08 |
센주 세이야꾸 가부시키가이샤 |
각막 내피 세포 접착 촉진제
|
WO2009151845A1
(en)
*
|
2008-05-12 |
2009-12-17 |
Amnestix, Inc. |
Compounds for rho kinase inhibition and for improving learning and memory
|
MX2010013974A
(es)
|
2008-06-24 |
2011-01-14 |
Sanofi Aventis |
Isoquinolinas e isoquinolinonas 6-sustituidas.
|
RU2538588C2
(ru)
|
2008-06-24 |
2015-01-10 |
Санофи-Авентис |
ЗАМЕЩЕННЫЕ ИЗИХИНОЛИНЫ И ИЗОХИНОЛИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
|
US8524737B2
(en)
|
2008-06-24 |
2013-09-03 |
Sanofi |
Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
|
EP2319539A4
(de)
|
2008-07-24 |
2012-03-28 |
Univ Osaka |
Prophylaktischer oder therapeutischer wirkstoff gegen axiale myopie
|
WO2010032875A2
(en)
*
|
2008-09-18 |
2010-03-25 |
Astellas Pharma Inc. |
Heterocyclic carboxamide compounds
|
EP2177218A1
(de)
|
2008-10-15 |
2010-04-21 |
Medizinische Universität Wien |
Regenerative Therapie
|
EP2177510A1
(de)
|
2008-10-17 |
2010-04-21 |
Universität des Saarlandes |
Allosterische Proteinkinasemodulatoren
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
AR078033A1
(es)
|
2009-04-03 |
2011-10-12 |
Plexxikon Inc |
Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
WO2011021221A2
(en)
|
2009-08-17 |
2011-02-24 |
Reliance Life Sciences Pvt. Ltd. |
Compositions for spinal cord injury
|
EP2488630B1
(de)
|
2009-10-16 |
2017-07-05 |
The Scripps Research Institute |
Induzierung pluripotenter zellen
|
NZ599866A
(en)
|
2009-11-06 |
2014-09-26 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
CN102188697B
(zh)
*
|
2010-03-03 |
2014-11-05 |
中国医学科学院药物研究所 |
重组人Rho激酶在制备药物中的应用
|
CA2797033C
(en)
|
2010-04-22 |
2021-10-19 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
AU2011349446C1
(en)
|
2010-12-22 |
2016-01-21 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
PE20141360A1
(es)
|
2011-02-07 |
2014-10-13 |
Plexxikon Inc |
Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
EP2628482A1
(de)
|
2012-02-17 |
2013-08-21 |
Academisch Medisch Centrum |
Rho Kinase Inhibitoren in der Verwendung zur Behandlung von Neuroblastoma
|
US9273006B2
(en)
*
|
2012-05-08 |
2016-03-01 |
Syddansk Universitet |
Anabolic compounds for treating and preventing bone loss diseases
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
BR112015001459B1
(pt)
|
2012-07-25 |
2023-02-14 |
Celldex Therapeutics, Inc |
Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
WO2014145718A2
(en)
|
2013-03-15 |
2014-09-18 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
EP3626245B1
(de)
|
2013-04-24 |
2021-05-05 |
Kyushu University, National University Corporation |
Therapeutikum für erkrankungen des augenhintergrunds
|
WO2014177699A1
(en)
*
|
2013-05-03 |
2014-11-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
|
CA2914369C
(en)
|
2013-06-06 |
2023-02-14 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
WO2015053871A2
(en)
|
2013-08-26 |
2015-04-16 |
MabVax Therapeutics, Inc. |
NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EP3604499A1
(de)
|
2014-03-04 |
2020-02-05 |
Fate Therapeutics, Inc. |
Verbesserte neuprogrammierungsverfahren und zellkulturplattformen
|
ES2863074T3
(es)
|
2014-06-04 |
2021-10-08 |
Biontech Res And Development Inc |
Anticuerpos monoclonales humanos contra el gangliósido GD2
|
CA2953524A1
(en)
|
2014-06-27 |
2015-12-30 |
The Regents Of The University Of California |
Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
|
KR20170087500A
(ko)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
US10149856B2
(en)
|
2015-01-26 |
2018-12-11 |
BioAxone BioSciences, Inc. |
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
|
US10106525B2
(en)
|
2015-01-26 |
2018-10-23 |
BioAxone BioSciences, Inc. |
Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
|
US10857157B2
(en)
|
2015-01-26 |
2020-12-08 |
BioAxone BioSciences, Inc. |
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
|
US10988534B2
(en)
|
2015-02-09 |
2021-04-27 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
|
AU2016227493B2
(en)
|
2015-03-03 |
2022-01-20 |
Kymab Limited |
Antibodies, uses & methods
|
WO2016210190A1
(en)
|
2015-06-24 |
2016-12-29 |
Nitto Denko Corporation |
Ionizable compounds and compositions and uses thereof
|
EP4088719A1
(de)
|
2015-10-13 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
|
US20180296474A1
(en)
|
2015-10-13 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
CA3001917A1
(en)
|
2015-10-16 |
2017-04-20 |
Fate Therapeutics, Inc. |
Platform for the induction & maintenance of ground state pluripotency
|
EP3383908A1
(de)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
|
US10875920B2
(en)
|
2015-12-02 |
2020-12-29 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US11198680B2
(en)
|
2016-12-21 |
2021-12-14 |
BioAxone BioSciences, Inc. |
Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
|
EP3630835A1
(de)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
|
KR20200024158A
(ko)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
WO2019014322A1
(en)
*
|
2017-07-11 |
2019-01-17 |
BioAxone BioSciences, Inc. |
KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Thomsen-nouvelle(tn)抗原に対するヒト抗体
|
TWI788484B
(zh)
|
2017-12-21 |
2023-01-01 |
日商參天製藥股份有限公司 |
賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
|
JP2021531007A
(ja)
|
2018-07-20 |
2021-11-18 |
ピエール、ファーブル、メディカマン |
Vistaに対する受容体
|
EP3843845A4
(de)
|
2018-08-29 |
2022-05-11 |
University Of Massachusetts |
Hemmung von proteinkinasen zur behandlung von friedreich-ataxie
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
CN111116555B
(zh)
*
|
2018-10-30 |
2023-06-02 |
北京盈科瑞创新药物研究有限公司 |
一种Rho激酶抑制剂及其制备方法和应用
|
WO2020193802A1
(en)
|
2019-03-28 |
2020-10-01 |
Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe |
Polymeric conjugates and uses thereof
|
CN115667504A
(zh)
|
2020-04-27 |
2023-01-31 |
诺华股份有限公司 |
用于眼细胞疗法的方法和组合物
|
CN111707831A
(zh)
*
|
2020-07-16 |
2020-09-25 |
首都医科大学附属北京朝阳医院 |
Rock激酶活性在辅助诊断sle以及评价sle病情中的应用
|
KR20230157307A
(ko)
|
2021-01-11 |
2023-11-16 |
인사이트 코포레이션 |
Jak 경로 억제제 및 rock 억제제를 포함하는 병용 요법
|
CN113262226B
(zh)
*
|
2021-04-19 |
2023-05-16 |
杭州市第一人民医院 |
利舒地尔在制备细菌感染治疗药物中的应用
|
CA3235384A1
(en)
|
2021-10-18 |
2023-04-27 |
Takahiro Ochiya |
Compositions and methods of use thereof for treating liver fibrosis
|
WO2023067394A2
(en)
|
2021-10-22 |
2023-04-27 |
Evia Life Sciences Inc. |
Methods for making extracellular vesicles, and compositions and methods of use thereof
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|